COMMUNIQUÉS West-GlobeNewswire

Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
07/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked [...]
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
07/10/2025
BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation [...]
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
07/10/2025
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina
07/10/2025
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across drug substance and [...]
Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings
07/10/2025
Torino, Italy, October 7 – Resalis Therapeutics , a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class antisense [...]
New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 World Muscle Society Congress
07/10/2025
Long-term treatment with givinostat in boys with Duchenne muscular dystrophy continues to show a favourable safety and tolerability profile Consistent efficacy demonstrated across age groups MILAN, Italy, October 07, [...]
Salipro Biotech Strengthens Global IP Portfolio with Two New Japanese Patents
07/10/2025
The two new patents expand protection for Salipro Biotech's proprietary technology for stabilizing and extracting challenging membrane proteins, crucial for developing therapeutics against high-value drug targets like [...]
Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer
07/10/2025
Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260 THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer Oxford UK, [...]
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
07/10/2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Cellectis présentera des données sur son programme de thérapie génique non-virale et sur des TALE Base Editors lors du congrès annuel de l’ESGCT
07/10/2025
NEW YORK, 07 oct. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des [...]
Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidate
07/10/2025
Former GSK and Sanofi executive, led Cervarix ® development and advanced pioneering therapies for rare diseases, decade of experience as venture capitalist Strengthens Bioxodes leadership following encouraging Phase 2a [...]
Bioxodes nomme Philippe Monteyne, un vétéran de l’industrie pharmaceutique, au poste de président et accélère le développement en phase avancée de son candidat médicament innovant dans l’AVC
07/10/2025
Ancien dirigeant de GSK et de Sanofi, M. Monteyne a supervisé le développement de Cervarix ® et permis l’avancement de plusieurs traitements pionniers dans les maladies rares ; il apporte dix années d’expérience en [...]
Allegro showcases superior shock-absorbing capacity of injectable hydrogel for osteoarthritis at CellMech
07/10/2025
Comparative testing against four market-leading hydrogels demonstrates Hydrocelin’s superior shock absorbing capacity Significantly improves the shock-absorbing capacity of pathological equine synovial fluid in [...]
Carlsbad Dental Care Expands Access to Modern Dentistry with New Patient Special and Financing Options
07/10/2025
Carlsbad, CA, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Carlsbad Dental Care, a trusted local practice led by Dr. Raymond Ngo, is improving access to high-quality dental care for families across the Carlsbad community with its [...]
Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress
07/10/2025
Single dose of avigbagene parvec (FLT201) demonstrates sustained clinical benefit and favorable safety up to two years after withdrawal of prior chronic therapy Data underscore potential to set new standard-of-care [...]
Scottish Rite for Children Ranked No. 1 for Pediatric Orthopedic Care by U.S. News & World Report
07/10/2025
Hospital has been recognized as one of the nation’s premier centers for 17 years Dallas, Oct. 07, 2025 (GLOBE NEWSWIRE) -- U.S. News & World Report ranked No. 1 in the nation for pediatric orthopedic care in its [...]
Children’s National ranked top hospital in the nation by U.S. News & World Report
07/10/2025
Washington, DC, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Children’s National Hospital once again ranked among the nation’s best by U.S. News & World Report Ranked in all specialties, with top 10 honors in neurology and [...]
Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements
07/10/2025
WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended [...]
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
07/10/2025
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$21.9 million on Ryoncil [...]

Pages